Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?

Core Viewpoint - Nektar Therapeutics has experienced a significant decline in share price, losing approximately 38.8% over the past month, which is worse than the S&P 500 performance [1] Group 1: Earnings and Estimates - The consensus estimate for Nektar has increased by 12.5% over the past month, indicating a positive trend in estimates [2] - Nektar's most recent earnings report is crucial for understanding potential catalysts for the stock [1] Group 2: VGM Scores - Nektar has a Growth Score of D, a Momentum Score of A, and a Value Score of D, placing it in the bottom 40% for the value investment strategy [3] - The overall VGM Score for Nektar is C, which is relevant for investors not focused on a single strategy [3] Group 3: Outlook - The upward trend in estimates for Nektar is promising, and the stock holds a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4] Group 4: Industry Comparison - Nektar is part of the Zacks Medical - Drugs industry, where Catalyst Pharmaceutical has seen a 2.8% increase in share price over the past month [5] - Catalyst reported revenues of $141.82 million for the last quarter, reflecting a year-over-year growth of 28.3% [5] - Catalyst is expected to post earnings of $0.53 per share for the current quarter, representing a 39.5% increase from the previous year, with a Zacks Rank of 3 (Hold) [6]